logo

If you are having a medical emergency, please call
9-1-1 or go directly to the Emergency Room.


Click to Email us

Jacksonville 800.237.3846
Daytona Beach 800.555.6590
Lake Mary 877.357.3846

Our regular office hours are:
Monday - Friday 8AM to 5PM.

Read VISION and stay Informed

Our Newsletter

Research

Proud of our Team of Doctors

Publications, Presentations and Book Chapters

We are extremely proud of our Team of Doctors for participating and contributing their time and efforts in the following publications, presentations and book chapters.

List of Publications by S.K. Steven Houston III, MD

Publications - Peer-reviewed

Mehta R, Ying GS, Houston S, Isakova T, Nessel L, Ojo A, Go A, Lash J, Kusek J, Grunwald J, Wolf M. Phosphate, Fibroblast Growth Factor 23 and Retinopathy in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort Study. Nephrol Dial Transplant. 2015; In Press.

Chen X, Rahimy E, Sergott RC, Nunes RP, Souza EC, Choudhry N, Cutler NE, Houston SK, Munk MR, Fawzi AA, Mehta S, Hubschman JP, Ho AC, Sarraf D. Spectrum of retinal vascular diseases associated with paracentral acute middle maculopathy. Am J Ophthalmol 2015 [epub ahead of print].

Houston SK, Rayess NM, Cohen M, Ho AC, Regillo CD. Influence of vitreomacular interface on anti-VEGF therapy using treat and extend treatment protocol for age-related macular degeneration (VINTREX). RETINA 2015; in press.

Williams AL, Greven M, Houston SK, Mehta S. Saturday night retinopathy: case report and a review of the literature. JAMA Ophthalmol 2015; in press.

Juhn AT, Houston SK, Mehta S. Bilateral Straatsma Syndrome with nystagmus. Retinal Cases and Brief Reports 2015; in press.

Sharma P, Juhn A, Houston SK, Fineman M, Chiang A, Ho AC, Regillo CD. Efficacy of intravitreal Ocriplasmin on vitreomacular traction and full-thickness macular holes. Am J Ophthalmol 2015 [epub ahead of print].

Rayess NM, Houston SK, Gupta OP, Ho AC, Regillo CD. Three year treatment outcomes for neovascular age-related macular degeneration using a "treat and extend" regimen. Am J Ophthalmol 2015;159(1):3-8.

Shah NV, Pham D, Murray TG, Decatur C, Hernandez E, Shah NN, Cavalcante M, Houston SK. Intravitreal and subconjunctival melphalan for retinoblastoma in transgenic mice. J Ophthalmol 2014;epub 2014.

Shah NV, Houston SK, Markoe AM, Murray TG. Combination therapy with triamcinolone acetonide and bevacizumab for the treatment of severe radiation maculopathy in patients with posterior uveal melanoma. Clin Ophthalmol 2013;7:1877-1882.

Houston SK, Lonngi M, Murray TG. Surgical management of posterior uveal melanoma: trends and developments. Exp Rev Ophthalmol 2013;8(4):393-99.

Shah NV, Houston SK, Murray TG. Retinoblastoma and treatment: a current evaluation of advanced therapy. World J Pharmacol 2013; 2(3):65-72.

Houston SK, Murray TG, Lampidis TJ. Models and discovery in retinoblastoma. Expert Opin Drug Discov 2013;8(4):383-94.

Houston SK, Shah NV, Decatur C, Lonngi M, Feuer W, Markoe AM, Murray TG. Intravitreal bevacizumab combined with plaque brachytherapy reduces melanoma tumor volume and enhances the resolution of exudative detachment. Clin Ophthalmol 2013;7:193-8.

Lonngi M, Houston SK, Murray TG, et al. Microincisional vitrectomy for retinal detachment in I-125 brachytherapy treated patients with posterior uveal malignant melanoma. Clin Ophthalmol 2013;7:427-35.

Shah NV, Houston SK, Markoe AM, Feuer W, Murray TG. Early SD-OCT diagnosis followed by prompt treatment of radiation maculopathy using intravitreal bevacizumab maintains functional visual acuity. Clin Ophthalmol 2012;6:1739-48.

Steven Houston SK, Shah NV, Murray TG. Intraoperative ultrasound aids plaque positioning. Ophthalmology 2012;119(11):2419-20.

Parke III DW, Sisk RA, Houston SK, Murray TG. Ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification. Clin Ophthalmol 2012;6:925-931.

Pina Y, Houston SK, Murray TG, Koru-Sengul T, Decatur C, Scott WK, Nathanson L, Clarke J, Lampidis TJ. Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-D-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumors. Clin Ophthalmol 2012;6:817-30.

Shah NV, Houston SK, Murray TG, Markoe AM. Evaluation of the surgical learning curve for I-125 episcleral plaque placement for the treatment of posterior uveal melanoma: a two decade review. Clin Ophthalmol 2012;6:447-52.

Houston SK, Wykoff CC, Berrocal AM, Hess DJ, Murray TG. Lasers for the treatment of intraocular tumors. Lasers Med Sci 2012; Feb 3 [epub ahead of print].

Pina Y, Decatur C, Murray TG, Houston SK, Lopez-Cavalcante M, et al. Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FDG), to target the chemoresistive hypoxic regions in LH(BETA)T(AG) retinal tumors. Invest Ophthalmol Vis Sci 2012;53(2):996-1002.

Houston SK, Murray TG. Microarray gene-expression analysis in ocular oncology: uveal melanoma and retinoblastoma. Expert Rev Ophthalmol 2011;6(4):477-85.

Houston SK, Wykoff CC, Berrocal AM, Hess DJ, Murray TG. Laser treatment for retinopathy of prematurity. Lasers Med Sci 2011; Dec 2 [epub ahead of print].

Houston SK, Markoe AM, Boldt HC, Murray TG. Juxtapapillary uveal melanomas: patient outcomes after treatment with proton irradiation for peripapillary and parapapillary melanomas (Editorial). Arch Ophthalmol 2011;129(9):1218-20.

Houston SK, Pina Y, Murray TG, et al. Regional and temporal differences in gene expression of LH(BETA)T(AG) retinoblastoma tumors. Invest Ophthalmol Vis Sci 2011; 52(8):5359-68.

Houston SK, Berrocal AM, Murray TG. The future of diagnostic imaging in retinoblastoma. JAAPOS 2011; 15(2): 125-6.

Pina Y, Decatur C, Murray TG, Houston SK, et al. Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LH(BETA)T(AG) retinal tumors. Clin Ophthalmol 2011; 5: 337-43.

Wykoff CC, Houston SK, et al. Anti-vascular endothelial growth factor agents for pediatric retinal diseases. Int Ophthalmol Clin 2011;51(1): 185-99.

Houston SK, Murray TG, et al. Current Update on Retinoblastoma. Int Ophthalmol Clin 2011; 51(1): 77-91.

Houston SK, Pina Y, Murray TG, et al. Novel Retinoblastoma treatment avoids chemotherapy: The effect of optimally-timed combination therapy with angiogenic and glycolytic inhibitors on LH(BETA)T(AG) retinoblastoma tumors. Clin Ophthalmol 2011; 27(5): 129-37.

Pina Y, Houston SK, Murray TG, et al. Focal, periocular delivery of 2-deoxy-D-glucose as adjuvant to chemotherapy for treatment of advanced retinoblastoma. Invest Ophthalmol Vis Sci 2010; 51(12): 6149-56.

Pina Y, et al., Houston SK (6th author) – Ophthalmic vasculature alterations following systemic chemotherapy and periocular Carboplatin of advanced retinoblastoma. J Pediatr Ophthalmol Strabismus 2010; Sep 22; 47 Online: e1-5.

Steven Houston SK, Ghazi NG, Morgan O, Olsakovsky L, Phillips P. A novel approach to processing DSAEK specimens for histopathologic analysis. Cornea 2010; 29(12): 1452-4.

Steven Houston SK, Weber ED, Koga SF, Newman SA. Novel applications of rarebit perimetry. J Neuroophthalmol 2010; 30(3): 243-7.

Houston SK, Ghazi NG, Bourne TD, Lopes MB. Bilateral massive retinal gliosis associated with Retinopathy of Prematurity. Arch Pathol Lab Med 2009; 133(8): 1242-45.

Presentations

Houston SK, Rayess NM, Cohen M, Ho AC, Regillo CD. Influence of vitreomacular interface on anti-VEGF therapy using treat and extend treatment protocol for age-related macular degeneration (VINTREX). Paper presentation at Retina Society, Philadelphia, PA, September 2014.

Rayess NM, Houston SK, Ho AC, Regillo CD. Long term treatment outcomes for neovascular age-related macular degeneration using a "treat and extend" regimen. Paper presentation at Retina Society, Philadelphia, PA, September 2014.

Chiang A, Houston SK, Juhn AT, Cohen M, Vander J, Regillo CD, Ho AC. Effect of Aflibercept on Refractory Macular Edema Associated with Central Retinal Vein Occlusion. Paper presentation at Retina Society, Philadelphia, PA, September 2014.

Houston SK, Rayess NM, Cohen M, Ho AC, Regillo CD. Influence of vitreomacular interface on anti-VEGF therapy using treat and extend treatment protocol for age-related macular degeneration (VINTREX). Paper presentation at American Society of Retina Specialists (ASRS) annual meeting, San Diego, CA, August 2014.

Regillo CD, Rayess NM, Houston SK, Ho AC. Long term treatment outcomes for neovascular age-related macular degeneration using a "treat and extend" regimen. Paper presentation at American Society of Retina Specialists (ASRS) annual meeting, San Diego, CA, August 2014.

Cohen M, Houston SK, Juhn AT, Chiang A, Vander J, Regillo CD, Ho AC. Effect of Aflibercept on Refractory Macular Edema Associated with Central Retinal Vein Occlusion. Poster presentation at American Society of Retina Specialists (ASRS) annual meeting, San Diego, CA, August 2014.

Shah NV, Houston SK, Markoe AM, Murray TG. Incidence of radiation retinopathy in patients with uveal melanoma treated with I-125 plaque brachytherapy at a single institution. American Academy of Ophthalmology (AAO) annual meeting, poster presentation 2013.

Houston SK, Shah N, Decatur CL, Lonngi M, Feuer WJ, Murray TG. Intravitreal bevacizumab as an adjuvant agent to plaque brachytherapy reduces tumor burden and enhances the resolution of exudative detachment. Association for Research in Vision and Ophthalmology (ARVO) poster 2012.

Shah N, Houston SK, Feuer WJ, Murray TJ. Effect of early SD-OCT diagnosis followed by prompt treatment of radiation retinopathy with anti-VEGF agents on visual acuity. Association for Research in Vision and Ophthalmology (ARVO) poster 2012.

Lonngi M, Murray TG, Sisk RA, Parke III DW, Berrocal AM, Houston SK. Combined microincisional vitrectomy and phacoemulsification in the management of complications associated with 125-I brachytherapy treated patients with uveal malignant melanoma. Association for Research in Vision and Ophthalmology (ARVO) poster 2012.

Cavalcante ML, Shah NV, Houston SK, Murray TG, Markoe AM. Evaluation of learning curve for 125-Iodine plaque brachytherapy placement: a 19 year review. Association for Research in Vision and Ophthalmology (ARVO) poster 2012.

Decatur CL, Shah N, Pina Y, Lonngi M, Pham D, Houston SK, Murray TG. Use of AMP-kinase activator 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) in the treatment of retinoblastoma. Association for Research in Vision and Ophthalmology (ARVO) poster 2012.

Shah NN, Houston SK, Pina Y, Murray TG, Decatur CL, Merchan J, Lampidis T. 2-deoxy-D-glucose (2-DG): In vivo evaluation of anti-angiogenic impact on retinoblastoma tumor vasculature. Association for Research in Vision and Ophthalmology (ARVO) poster 2012.

Houston SK, Murray TG, Pina Y, Decatur C. Treatment of LH(BETA)T(AG) retinoblastoma tumors with angiogenic and glycolytic inhibitors avoids chemotherapy. International Society of Ocular Oncology (ISOO) presentation 2011.

Houston SK, Murray TG, Markoe AM, Pina Y, Decatur C. Intravitreal bevacizumab as an adjuvant agent when used immediately after treatment with plaque brachytherapy. International Society of Ocular Oncology (ISOO) presentation 2011.

Pina Y, Decatur C, Houston SK, Murray TG, Cavalcante L, Lampidis T. Using the glycolytic inhibitor 2-fluorodeoxy-D-glucose, a novel approach to target the chemoresistant cell population in LH(BETA)T(AG) retinal tumors. International Society of Ocular Oncology (ISOO) presentation 2011.

Murray TG, Pina Y, Decatur CL, Houston SK, Cavalcante L, Lampidis L. mTOR targeting in combination with chemotherapy: upstream regulation of anaerobic glycolysis to target the chemoresistant cell population in RB. International Society of Ocular Oncology (ISOO) presentation 2011.

Murray TG, Houston SK, Aziz-Sultan MA, Fernandes CE, Decatur C, Pina Y. Intra-arterial melphalan dosing regimens for the treatment of retinoblastoma. International Society of Ocular Oncology (ISOO) presentation 2011.

Decatur C, Pina Y, Houston SK, Cavalcante L, Lampidis T, Murray TG. A novel, oral, non-invasive method of delivery for the glycolytic inhibitor 2-deoxy-D-glucose in the treatment of retinoblastoma. International Society of Ocular Oncology (ISOO) presentation 2011.

Murray TG, Houston SK, Decatur CL, Shah N, Cavalcante L, Pina L. Treatment modulation in retinoblastoma tumorigenesis and its impact on tumor burden. International Society of Ocular Oncology (ISOO) poster 2011.

Decatur CL, Pina Y, Houston SK, Sullivan E, Liu H, Lampidis T, Murray TG. Evaluating the glycolytic pathway in retinoblastoma: a mechanistic approach using the glycolytic inhibitor 2-deoxy-D-glucose in vitro and in vivo. International Society of Ocular Oncology (ISOO) poster 2011.

Pina Y, Murray TG, Decatur CL, Shah N, Cavalcante L, Houston SK. Regional and temporal variations in gene expression and vasculature during retinoblastoma tumorigenesis and its impact on ocular treatment. International Society of Ocular Oncology (ISOO) poster 2011.

Murray TG, Houston SK, Aziz-Sultan MA, Fernandes CE. Strategies for chemotherapeutic dosing utilizing intra-arterial melphalan chemotherapy for primary and rescue treatment for pediatric retinoblastoma. ASRS presentation 2011.

Houston SK, Murray TG, Decatur CL, Pina Y, Cavalcante L, Lampidis T. Use of 2-fluorodeoxy-D-glucose (2-FDG) to target the chemoresistant, hypoxic cell population in advanced LH(BETA)T(AG) retinal tumors. Association for Research in Vision and Ophthalmology (ARVO) poster 2011.

Pina Y, Decatur CL, Houston SK, Cavalcante L, Lampidis T, Murray TG. Mammalian target of rapamycin in combination with chemotherapy: upstream regulation of anaerobic glycolysis to target the chemoresistant cell population in retinoblastoma. Association for Research in Vision and Ophthalmology (ARVO) poster 2011.

Decatur CL, Pina Y, Houston SK, Cavalcante L, Murray TG, Lampidis T. Evaluating the glycolytic pathway in retinoblastoma: a molecular mechanistic approach using the glycolytic inhibitor 2-deoxy-D-glucose in vitro and in vivo. Association for Research in Vision and Ophthalmology (ARVO) poster 2011.

Murray TG, Decatur CL, Pina Y, Houston SK, Cavalcante L, Lampidis T. A novel, oral, non-invasive method of delivery for the glycolytic inhibitor 2-deoxy-D-glucose in the treatment of retinoblastoma. Association for Research in Vision and Ophthalmology (ARVO) poster 2011.

Houston SK, Decatur CL, Murray TG, Shah N, Cavalcante L, Pina Y. Novel treatment approaches in retinoblastoma: impact of combination therapy on tumor burden. American Association of Cancer Research (AACR) poster 2011.

Murray TG, Pina Y, Decatur CL, Houston SK. Anti-angiogenic agents combined with chemotherapy targets tumor vasculature and decreases tumor burden. American Association of Cancer Research (AACR) poster 2011.

Pina Y, Murray TG, Houston SK, Decatur CL. Tumor associated macrophages as potential targets in retinoblastoma tumors. American Association of Cancer Research (AACR) poster 2011.

Decatur CL, Pina Y, Houston SK, Murray TG. Non-invasive, oral 2-deoxy-D-glucose (2-DG) reduces tumor burden and hypoxia in LH(BETA)T(AG) retinoblastoma tumors. American Association of Cancer Research (AACR) poster 2011.

Houston SK, Pina Y, Scott WK, Nathanson L, Schefler AC, Murray TG. Regional and temporal differences in the genetic expression of LH(BETA)T(AG) retinoblastoma tumors. Association for Research in Vision and Ophthalmology (ARVO) poster 2010.

Pina Y, Houston SK, Scott W, Nathanson L, Schefler AC, Lampidis T, Celdran M, Hernandez E, Murray TG. Retinoblastoma molecular genomics: regional differences in the molecular genomics expression following treatment with 2-deoxy-D-glucose in LH(BETA)T(AG) retinal tumors. Association for Research in Vision and Ophthalmology (ARVO) presentation 2010.

Murray TG, Pina Y, Houston SK, Hernandez E, Celdran M, Feuer W, Lampidis T. Retinoblastoma tumor burden control: periocular mTOR inhibitor rapamycin decreases tumor burden in advanced LH(BETA)T(AG) murine retinoblastoma. Association for Research in Vision and Ophthalmology (ARVO) poster 2010.

Green DP, Houston SK, Newman SA. Rarebit perimetry: number of test passes needed to identify visual field defects. Association for Research in Vision and Ophthalmology (ARVO) poster 2010.

Berrocal AM, Houston SK, Pina Y, Bascom Palmer Imaging Group, Murray TG. Intraoperative spectral domain optical coherence tomography (SD-OCT) imaging of complex pediatric retinal disease. Association for Research in Vision and Ophthalmology (ARVO) presentation 2010.

Houston SK, Weber ED, Newman SA, Koga SF. Novel applications of rarebit perimetry. Association for Research in Vision and Ophthalmology (ARVO) poster 2009.

Houston SK, Ghazi NG. Bilateral massive retinal gliosis in a patient with bilateral retinal detachment in the setting of retinopathy of prematurity. Association for Research in Vision and Ophthalmology (ARVO) poster 2008.

Book Chapters

Houston SK, Ho AC. Miscellaneous Macular Degenerations. Ed: Scott IU, Regillo CD, Flynn HW, Brown GC. Vitreoretinal Diseases: The Essentials 2014 (in press).

Houston SK, Garg SJ. Fundus photography and autofluorescence in AMD. Ed: A. Witkins Age-related Macular Degeneration 2014 (in press).

Houston SK, Markoe AM, Boldt HC, Murray TG. Brachytherapy for uveal melanoma. In: Ryan SJ, ed. RETINA, 5th edition. Philadelphia, PA: Elsevier/Mosby, 2012: Chapter 145.

Houston SK, Pina Y, Murray TG. Future Trends in Retinoblastoma. In: Ramasubramanian A, Shields C, ed. Retinoblastoma, 1st edition. Panama: Jaypee-Highlights Medical Publishers, Inc., 2012: Chapter 36.

Houston SK, Murray TG. Chapter 2: Laboratory Discoveries. Retinoblastoma: Clinical advances and emerging treatment strategies. Ed: Timothy G. Murray, Future Medicine, 1st edition.

Houston SK, Murray TG. Chapter 9: Retinoblastoma treatment. Retinoblastoma: Clinical advances and emerging treatment strategies. Ed: Timothy G. Murray, Future Medicine, 1st edition.

Houston SK, Boldt HC, Murray TG. Chapter 10: Brachytherapy for uveal melanoma. Ocular melanoma: advances in diagnostic and therapeutic strategies. Ed: Timothy G. Murray and Culver Boldt, Future Medicine, 1st edition.

Houston SK, Murray TG. Chapter 17: Surgical management of radiation-related complications. Ocular melanoma: advances in diagnostic and therapeutic strategies. Ed: Timothy G. Murray and Culver Boldt, Future Medicine, 1st edition.